NEW YORK (GenomeWeb) – SeraCare Life Sciences and Toma Biosciences announced today that they are entering into a codevelopment partnership.

Terms of the agreement call for SeraCare to provide Toma with access to its Seraseq Solid Tumor Mutation mix reference material technology to support the development and validation of Toma OS-Seq, a comprehensive solid tumor gene analysis kit, and Toma's upcoming PlasmaSeq liquid biopsy test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.